No nit-picking from FDA on new lice drug
Executive Summary
Sciele Pharma's benzyl alcohol lotion, 5 percent received FDA approval April 9 for the treatment of head lice in patients six months of age and older, making it the first head lice product approved by the agency with benzyl alcohol as the active pharmaceutical ingredient. Approval was based on two placebo-controlled studies of 628 subjects with active head lice infestation; 14 days following the final treatment, more than 75 percent of the subjects treated with the drug were lice-free
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.